Recombinant Human Thrombopoietin Injection.

Effects and efficacy:
It is suitable for the treatment of thrombocytopenia caused by chemotherapy for solid tumors. It is suitable for patients with platelet counts below 50×109/L and doctors believe that it is necessary to increase platelet counts for treatment. This product is used as an adjuvant treatment for idiopathic thrombocytopenic purpura (ITP). It is suitable for patients with platelet counts below 20×109/L who have not received splenectomy and have failed glucocorticoid treatment (including initial treatment failure, or recurrence after effective treatment and failure of re-treatment). This product is only used for patients with thrombocytopenia and clinical status with increased bleeding risk, and should not be used to try to raise the platelet count to normal values.
Usage and Dosage:
For thrombocytopenia caused by chemotherapy for malignant solid tumors, this product can be injected subcutaneously 6-24 hours after the end of administration, with a dose of 300U per kilogram of body weight per day, once a day, for 14 consecutive days; during the course of medication, when the platelet count recovers to above 100×10/L, or the absolute value of the platelet count increases by ≥50×10/L, it should be discontinued. When chemotherapy is accompanied by severe leukopenia or anemia, this product can be used in combination with recombinant human granulocyte colony-stimulating factor (rhG-CSF) or recombinant human erythropoietin (rhEPO). For idiopathic thrombocytopenic purpura (ITP) that is ineffective with glucocorticoid treatment, this product can be injected subcutaneously at a dose of 300U per kilogram of body weight per day, once a day, for 14 consecutive days; if the platelet count has risen to ≥100×10/L in less than 14 days, stop using this product. If bleeding occurs in the mouth, nose or internal organs, emergency treatment such as platelet transfusion and antifibrinolytic hemostatic drugs can be given.
Adverse reactions:
Adverse reactions rarely occur, and there are occasional mild adverse reactions, such as muscle aches, fever, chills, general discomfort, fatigue, knee pain, headache, dizziness, and increased blood pressure. Generally, no treatment is required and most patients can recover on their own. Symptomatic treatment can be given to individual patients when symptoms are obvious. When used as an adjuvant treatment for ITP that is ineffective with glucocorticoids, there is a low probability of mild drowsiness, mild dizziness, severe paroxysmal visual field loss, mild allergic-like reactions, mild rash, mild weakness, mild diarrhea, mild hypertension, and mild pain at the injection site.
Drug contraindications:
Contraindicated for allergic reactions to this product. Use with caution during pregnancy and lactation.